Home › Research › Biomarkers
Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort
Rudolph MD, Sutphen CL, Register TC, Lockhart SN, Rundle MM, Hughes TM, Bateman JR, Sai KKS et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Studies suggest excellent performance of plasma phosphorylated tau 217 (p-tau217) for detecting amyloid pathology, though studies in more representative populations are needed to validate previously determined cutpoints. Methods Plasma p-tau217 utility for detecting amyloid pathology (Aβ) via amyloid positron emission tomography (PET) was assessed in a heterogeneous, community-based cohort in the Wake Forest Alzheimer's Disease Research Center (WFADRC). Participants with baseline plasma data (n = 598) were 21% Black; 313 cognitive unimpaired (CU), 214 mild cognitive impairment (MCI), and 64 dementia (DEM); 49% prediabetic, 44% hypertensive, 29% overweight/obese; and 64% had mild-to-moderate kidney disease. Gaussian-mixture models, logistic regression, and receiver operating curve analyses were performed. Results Plasma p-tau217 was associated with elevated Aβ deposition and accurately classified Aβ-positive participants (PET [n = 307]: area under the curve [AUC] = 94%-97%, cutpoint ≥ 0.338 pg/mL). Discussion Plasma p-tau217 is an accurate indicator of amyloid pathology in a heterogeneous cohort and is superior to other plasma biomarkers assessed. Highlights The Wake Forest Alzheimer's Disease Research Center (WFADRC) is a heterogeneous cohort. p-tau217 levels were lower, on average, in cognitively unimpaired participants, females, and Black participants. Plasma p-tau217 classified amyloid positron emission tomography (PET)-positive individuals with high precision and performed better than p-tau181. Cutpoints and reference ranges of plasma p-tau217 were lower compared to recently published thresholds. Combining cutpoint approaches, a four-tier system captured cohort heterogeneity.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rudolph, M. D., Sutphen, C. L., Register, T. C., Lockhart, S. N., Rundle, M. M., Hughes, T. M., et al. (2025). Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70426
Vancouver
Rudolph MD, Sutphen CL, Register TC, Lockhart SN, Rundle MM, Hughes TM, et al. Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70426. PMID: 40613474.
BibTeX
@article{rudolph2025-40613474,
author = {Rudolph, M. D. and Sutphen, C. L. and Register, T. C. and Lockhart, S. N. and Rundle, M. M. and Hughes, T. M. and Bateman, JR. and Sai, K. K. S. and others},
title = {{Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70426},
pmid = {40613474},
url = {https://doi.org/10.1002/alz.70426}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Plasma p-tau217 was associated with elevated Aβ deposition and accurately classified Aβ-positive participants (PET [n = 307]: area under the curve [AUC] = 94%-97%, cutpoint ≥ 0.338 pg/mL).
- Cutpoints and reference ranges of plasma p-tau217 were lower compared to recently published thresholds.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants598
- Evidence strengthModerate
How this study scored 60/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 35 of the 58 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 598 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40613474) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 35 of the 58 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.